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Highlights: 
 
x A synthetic lethal screen for Poly(ADP-ribose)glycohydrolase (PARG) 
is presented. 
x SiRNA and the PARG inhibitors Gallotannin and PDD00017273 are 
used. 
x PARG is synthetically lethal with BRCA1, BRCA2, PALB2, FAM175A 
(ABRAXAS) and BARD1. 
x PARG inhibition induces DNA damage, stalled replication forks and 
homologous recombination. 
x The data support the validity of PARG as a target for therapy. 
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Abstract 
Poly(ADP-ribosylation) of proteins following DNA damage is well studied and 
the use of poly(ADP-ribose) polymerase (PARP) inhibitors as therapeutic 
agents is an exciting prospect for the treatment of many cancers. Poly(ADP-
ribose) glycohydrolase (PARG) has endo-and exoglycosidase activities which 
can cleave glycosidic bonds, rapidly reversing the action of PARP enzymes. 
Like addition of poly(ADP-ribose) (PAR) by PARP, removal of PAR by PARG 
is also thought to be required for repair of DNA strand breaks and for 
continued replication at perturbed forks. Here we use siRNA to show a 
synthetic lethal relationship between PARG and BRCA1, BRCA2, PALB2, 
FAM175A (ABRAXAS) and BARD1. In addition, we demonstrate that MCF7 
cells depleted of these proteins are sensitive to Gallotannin and a novel and 
specific PARG inhibitor PDD00017273. We confirm that PARG inhibition 
increases endogenous DNA damage, stalls replication forks and increases 
homologous recombination, and propose that it is the lack of homologous 
recombination (HRR) proteins at PARG inhibitor-induced stalled replication 
forks that induces cell death. Interestingly not all genes that are synthetically 
lethal with PARP result in sensitivity to PARG inhibitors, suggesting that 
although there is overlap, the functions of PARP and PARG may not be 
completely identical. These data together add further evidence to the 
possibility that single treatment therapy with PARG inhibitors could be used 
for treatment of certain HRR deficient tumours and provide insight into the 
relationship between PARP, PARG and the processes of DNA repair. 
Keywords 
Synthetic lethality, breast cancer, PARG inhibition, FAM175A (ABRAXAS), 
BRCA1, PALB2, BARD1  
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1. Introduction  
An early response to DNA damage is the addition of poly(ADP-ribose) (PAR) 
to proteins 1,2. This post-translational modification has been implicated in 
repair of single 3-7 and double strand DNA breaks 8-11 and in the restart of 
stalled or collapsed DNA replication forks 12-14. In each case, poly(ADP-
ribose) polymerase (PARP) enzymes are recruited to and activated at sites of 
damage. Using NAD as a substrate, they add multiple ADP-ribose subunits to 
gamma carboxyl groups of the glutamic acid residues of acceptor proteins 15. 
The PAR signal is then assumed to recruit other repair factors to the site of 
damage allowing DNA repair and/or continued DNA replication 11,14,16-18. 
 
We and others demonstrated that PARP inhibitors can specifically kill 
homologous recombination repair (HRR) deficient tumours 19,20. This is 
because, in the absence of PARP activity, increased numbers of replication 
forks collapse and HRR becomes essential for cell survival 14,19,21. 
Accordingly, inhibition of PARP has become a successful and increasingly 
promising therapeutic approach for certain tumour types 22. 
 
Nevertheless, PAR modification is reversible and it is proposed that once 
other repair proteins have localized to the damaged DNA, PAR needs to be 
removed before repair can take place 6. Poly(ADP-ribose) glycohydrolase 
(PARG) has endo-and exoglycosidase activities which can cleave glycosidic 
bonds, rapidly reversing the action of PARP enzymes and returning proteins 
to their native unmodified state 23-27. Like PARP, PARG is rapidly recruited to 
sites of DNA damage, and cells deficient in the nuclear form of PARG display 
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increased levels of genomic instability and are sensitive to DNA damaging 
agents 28-34. Consistent with an essential role in reversing PARP activity at 
sites of DNA damage, PARG activity is reported to contribute to the efficiency 
of DSB and SSB repair, to be required for recovery from prolonged replication 
stress and to have a role in resolving unusual replication structures in S-
phase 6,35-38. We previously demonstrated a synthetic lethal relationship 
between PARG and the HRR protein BRCA2, which was suggested to be due 
to increased collapsed replication forks that could not be resolved by HRR 39. 
Here we screen for other genetic alterations which maybe synthetic lethal with 
PARG, and further investigate the mechanism by which this occurs.  
 
We demonstrate that along with the previously shown BRCA2, BRCA1, 
PALB2, FAM175A (ABRAXAS) and BARD1 are all synthetic lethal with siRNA 
mediated depletion of PARG and with inhibition of PARG enzyme activity. We 
confirm directly that PARG inhibition leads to stalled replication forks and 
increased HRR. Further, we demonstrate that each of the genes above is 
required for efficient HRR, suggesting that, as with BRCA2, it is the lack of 
HRR proteins at PARG inhibitor-induced replication stalling that induces cell 
death. These data together add further evidence to the possibility that single 
treatment therapy with PARG inhibitors could be used for treatment of HRR-
deficient tumours. 
 
2. Material and Methods  
2.1 Cell culture 
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The MCF7 breast epithelial adenocarcinoma cell line was purchased from the 
American Type Culture Collection (ATCC® HTB-22TM). This cell line was 
JURZQ LQ'XOEHFFR¶VPRGLILHG(DJOH0HGLXP'0(0VXSSOHPHQWHGZLWK[
non-essential amino acids (NEAA, Sigma) and 10% Foetal bovine serum 
(Gibco) at 37qC under an atmosphere containing 5% CO2.  
 
2.2 Inhibitors 
The PARG inhibitor PDD00017273 40 was resuspended in DMSO at a 
concentration of 20 mM. Final concentrations were 0.3 µM and 1 µM unless 
otherwise stated. The commercially available PARG inhibitor, Gallotannin 
(C76H52O46) (GLTN) was purchased from Enzo Life Sciences (ALX-270-418). 
1000× stocks were prepared in sterile H2O and stored at -20qC. A final 
concentration of 10 µM was used. The PARP inhibitor, Olaparib was 
purchased from Cambridge Biosciences and prepared in DMSO to give a 
1000× stock. Unless otherwise stated, a final concentration of 1 µM was used. 
 
2.3 SiRNA screen 
A custom-made 96-well plate was purchased from Dharmacon (GE 
Healthcare) containing 4 individual ON-TARGETplus siRNA oligonucleotides 
for each of the following 18 genes; BRCA1 (NM_007298), BRCA2 
(NM_000059), PALB2 (NM_024675), RAD51C (NM_002876), CHEK2 
(NM_145862), RAD51D (NM_133629), BRIP1 (NM_032043), BARD1 
(NM_000465), MRE11A (NM_005591), NBN (NM_002485), RAD50 
(NM_133482), TP53 (NM_000546), PTEN (NM_000314), STK11 
(NM_000455), ATM (NM_138292), FAM175A (NM_139076), XRCC2 
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(NM_005431) and CDKN2A (NM_058195).  Each of the four were tested for 
efficiency of mRNA depletion and the two with greatest effect were taken 
forward into the screen. ON-TARGETplus siRNA was also purchased from 
Dharmacon for two individual PARG (NM_003631) siRNA oligonucleotides 
and the non-targeting siRNA #1 (scrambled) control. All siRNAs were 
resuspended at 5 µM in 1× siRNA universal buffer (Dharmacon) and stored at 
-20qC. In some experiments pools of four target gene siRNA or two PARG 
siRNA are used and in others the pools were deconvoluted and two individual 
siRNA used. This is indicated in each case. 
 
2.4 SiRNA transfection 
For the initial siRNA screen, cells were seeded in 96-well plates (five replica 
wells for each individual siRNA, co-transfected with either scrambled control 
or individual PARG siRNA. The following day, cells were co-transfected with 
20 nM siRNA (final concentration) using Dharmafect 4 reagent (Dharmacon) 
following manufacturer¶V¶ instructions. For further experiments, cells were co-
transfected with pooled siRNA (from the four individual siRNAs) for each gene 
and either scrambled control or pooled PARG siRNA (from the two individual 
siRNAs) at a final concentration of 20 nM using Dharmafect 4 reagent 
'KDUPDFRQ IROORZLQJ PDQXIDFWXUHU¶V LQVtructions. Knockdown was 
confirmed after 48 hours by real-time PCR or western blot. 
 
2.5 MTT assay 
Following siRNA transfection, cells were left for five days after which time, 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-DiphenyltetrazoliumBromide) 
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(ThermoFisher) 1 mg/ml) was added to each well and the cells left for 3 hours 
at 37qC. The media was then aspirated off and replaced with 200 µl DMSO 
(Fisher scientific) and the OD measured at 540 nm. From the five replicate 
wells, the highest and the lowest ODs were omitted and the average and 
standard deviation calculated from the remaining 3 replicates. This was 
carried out on at least 2 separate occasions and the average of 2 repeats 
calculated. (See supplementary material for workflow of screen analysis). 
 
2.6 Clonogenic survival assay 
Cells were transfected with siRNA for each of the genes of interest (as above) 
in 24-well plates and left for 48 hours before re-plating at known densities in 
90 mm dishes. When inhibitors were added to the media this was done 4 
hours after replating and then cells were left for 15 days to form colonies. The 
colonies were stained with 4% methylene blue in 70% methanol and counted. 
 
2.7 RNA extraction, cDNA synthesis and Real time PCR 
Total RNA was extracted using the GenEluteTM Mammalian Total RNA 
Miniprep kit (Sigma). cDNA was made using 100 µg total RNA and the 
Applied Biosystems High Capacity cDNA Reverse Transcriptase kit from 
ThermoFisher Scientific. 2 µl cDNA was mixed with SYBR Green PCR master 
mix (ThermoFisher Scientific) and 10 mM primers. Primers for each of the 18 
genes included in the screen as well as PARG were designed to amplify 
between 100±150bp cDNA transcripts.  
Primers were as follows:  
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BRCA1IRUZDUGƍ-ACAGCTGTGTGGTGCTTCTGTG, Reverse - ƍ-
CATTGTCCTCTGTCCAGGCATC, BRCA2IRUZDUGƍ-
*$$7*&&&&$7&*$77**7&$UHYHUVHƍ$*&&&&7$$$&&&&$&77&$7
PALB2IRUZDUGƍ-CCTGTGCCAAAGAGAGTGAGTC, reverse 
5`AGTCTGTACCCGACCATTTCAC, RAD51CIRUZDUGƍ- 
GATGACCTGTCT&77&*7$&7&UHYHUVHƍ-
TTAGCCGTATTGTAGCAGCATG, CHEK2IRUZDUGƍ-
*$7*&7&77**&7*7*&$*7$&UHYHUVHƍ-
GTTCCACATAAGGTTCTCATG, RAD51DIRUZDUGƍ- 
**&$77**&$*7&77*$7$$$&UHYHUVHƍ- 
ACATTTGCTGCCATACAGAGAC, BRIP1IRUZDUGƍ-
$&$7&*777**$7&$7*&&&7&UHYHUVHƍ-
AACAGAGCGGATGTTCAGAATG, BARD1IRUZDUGƍ-
7*&&$$$*&7*777*$7**$7*UHYHUVHƍ-
TGGTATGCGACTGTATTGATGG, MRE11IRUZDUGƍ-
&$$&&$$&$$$**$$*$**&UHYHUVHƍ-TAGTGACATTTCGGGAAGGC, 
NBN: forward 5`-7&7*7$$&&$$&&7*$*7&$$$&UHYHUVHƍ-
TCAAAGTTCGGGAAAAGCCATT, RAD50IRUZDUGƍ-
7*$**$&$$&$*$$&77*7*$$&UHYHUVHƍ-
TCCACGATAGGTACTTCGCC, TP53IRUZDUGƍ-
&&&$$*&$$7**$7*$777*$UHYHUVHƍ-
GGCATTCTGGGAGCTTCATCT, PTENIRUZDUGƍ-
*$$*$&&$7$$&&&$&&$&$*&UHYHUVHƍ-
ATTACACCAGTTCGTCCCTTTC, STK11IRUZDUGƍ-
CATGACTGTGGTGCC*7$&77*UHYHUVHƍ-
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TTGTGACTGGCCTCCTCTTCTG, ATMIRUZDUGƍ-
7*&7*$&$$7&$7&$&&$$*77&UHYHUVHƍ-
TCTCCCTTCGTGTCCTGGAA, FAM175AIRUZDUGƍ-
7&&$*&7$*7$&$&&$&$$$7&UHYHUVHƍ-CATCTGTTTCTGGGCTGCTC, 
XRCC2IRUZDUGƍ-&&7*7*&$7**7*$7$77&77*UHYHUVHƍ-
TTCCAGGCCACCTTCTGATTTG, CDKN2AIRUZDUGƍ-
&$7$*$7*&&*&**$$**7UHYHUVHƍ-CCCGAGGTTTCTCAGAGCCT 
and PARGIRUZDUGƍ-*&7*7*$$&&&7*&$&&$$*&UHYHUVHƍ-
AAACTTTCTGATTCCGCTGTC.  
U1 snRNA was used an endogenous gene control. Real-time PCR was 
carried out (1× 50qC for 2 min, 1× 95qC for 10 min, 40× 95qC for 15 seconds 
followed by 60qC for 1 min) using the Applied Biosystems (Carlsbad, CA, 
USA) 7900HT fast real time PCR system. Images and data were documented 
using the SDS Enterprise Database software (Applied Biosystems by Life 
Technologies). 
 
2.8 HRR assay using pDR-GFP 
Cells were plated in 6-well dishes and then either transfected with siRNA as 
above or incubated with inhibitors for 24 hours before transient transfection 
with 1.25 µg pDR-GFP and 1.25 µg pCMV-ISceI plasmids 41 using 
lipofectamine 2000 (Invitrogen) following WKHPDQXIDFWXUHU¶Vinstructions. After 
48 hours, cells were scraped into 200 µl cold phosphate buffered saline (PBS) 
and analysed for GFP expression using the 488 nm laser on a FACSCaliburTM 
flow cytometer (BD Biosciences). Data was analysed using Flowjo software 
(Flowjo, LLC) and the % of cells expressing GFP was normalised to the non-
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transfected control and then calculated as the fold difference from either 
scrambled or non-treated cells.  
 
2.9 DNA fibre analysis 
Cells were seeded in 6-well plates in media containing inhibitors. After 24 
hours 25 µM (final concentration) of CldU (Sigma) was added to cells for 20 
min at 37qC before 250 µM IdU (final concentration, Sigma) was added for a 
further 20 min at 37qC. DNA fibre analysis was then carried out as previously 
described 14. Immunofluorescence was visualized using an Olympus FV1000 
confocal BX61 upright microscope equipped with ×60(1.42 NA) objective lens. 
Images were captured and analyzed by Fluoview 3.1 software (Olympus, 
Shinjuku, Tokyo, Japan). Measurements of labelled tracks were performed in 
micrometres, by using the ImageJ software (http://rsbweb.nih.gov/ij/), and 
converted to kilobases with the factor 
1 ȝP  kb.  
 
2.10 Immunofluorescence 
Cells were plated onto coverslips and allowed to settle before transfecting 
with siRNA as described above. After 48 hours, medium was removed and 
cells washed with PBS. Cells were fixed in 4% paraformaldeyhyde solution 
(Insight Biotechnology) for 20 min at room temperature and then extensively 
washed (3× 5 min in (tris buffered saline (TBS), 1× 10 min in PBS containing 
0.5% Triton X-100 and 3× 5 min in TBS). Coverslips were placed in 10% goat 
serum in TBS for 1 hour at room temperature to block followed by a further 3× 
5 min washes in TBS prior to incubation with the primary antibody anti-Ȗ+$;
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(ser139) (Cell Signalling), (1:500 in TBS containing 3% goat serum) for 16 
hours at 4qC. The coverslips were subsequently washed 4× 10 min in TBS 
followed by incubation with the secondary antibody, Alexa fluor 594 goat anti-
rabbit IgG (Fisher) (1:500 in TBS containing 3% goat serum) for 1 hour at 
room temperature and finally washed 3× 5 min TBS. Coverslips were then 
mounted onto microscope slides with DAPI containing mountant (Vector 
Labs). Images were obtained with a Zeiss LSM 510 inverted confocal 
microscope using planapochromat 63×/NA 1.4 oil immersion objective and 
excitation wavelengths 488, 546 and 630 nm. Through focus maximum 
projection images were acquired from optical sections 0.5 µM apart and with a 
section thickness of 1.0 µm. Images were processed using Adobe Photoshop 
$EDFXV,QF7KHIUHTXHQF\RIFHOOVFRQWDLQLQJȖ+$;IRFLZDVGHWHUPLQHG
by counting at least 100 nuclei on each slide. 
 
2.11 Western blotting 
Cells were lysed in RIPA buffer in the presence of 1× protease and 
phosphatase inhibitor cocktails (Roche). An aliquot of 30 µg total protein was 
run on an SDS-PAGE gel and transferred to Hybond ECL membrane (GE 
Healthcare). This membrane was immunoblotted with antibodies against 
Poly(ADP-ribose) (1:400, 10H Enzo), PARG (1:250, Abcam), PARP1 (1:1000, 
Santa Cruz), BRCA1 (1:500, Santa Cruz), BARD1 (1:500, H-300, Santa 
Cruz), PTEN (1:1000, Cell Signalling), PALB2 (1:500, Novus Biologicals), 
)$0$%HWK\ODQGȕ-tubulin (1:2000, Sigma) each diluted in 5% 
milk and incubated at 4qC overnight. After the addition of the appropriate 
HRP-conjugated secondary antibody and further washes, the immunoreactive 
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protein was visualised using ECL reagents (GE Healthcare) following 
PDQXIDFWXUHU¶VLQVWUXFWLRQV 
 
3. Results 
3.1 An siRNA screen for synthetic lethality with PARG depletion. 
Previously PARG depletion or inhibition was shown to be synthetic lethal with 
depletion of BRCA2 39. Here, this work is extended to examine the synthetic 
lethal interactions of PARG with a range of known or putative DNA damage 
response (DDR) genes. Each of these genes has also been associated with 
breast cancer and the screen was performed in the breast cancer cell line 
MCF7 42. Four siRNAs against each target DDR gene were tested (oligos a-d 
± data not shown) and the two that reduced expression of their target mRNA 
the most (by at least 60%) were taken forward (figure 1A). Two separate 
siRNAs against PARG were also used and shown to reduce expression of 
PARG protein by 80-90% without significant change in PARP1 protein levels 
(figure 1B). Transfection with PARG siRNA alone did not significantly alter the 
survival of MCF7 cells (figure 1C). To initially examine synthetic lethality, 
combinations of each target DDR gene siRNA with each PARG siRNA were 
transfected into MCF7 cells along with the relevant controls and cell viability 
determined using an MTT assay (workflow in supplementary material). 
Depletion of each of the target DDR genes alone had a varied effect on cell 
viability (supplementary figure 1), therefore after normalizing for the effect of 
PARG depletion, the viable fraction of cells depleted of target DDR gene plus 
PARG was calculated relative to the viability of cells depleted of the 
corresponding target DDR gene alone. Although a reduction in viability is not 
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definitive of synthetic lethality (cell death), it does indicate genetic interactions 
and therefore in this initial screen a potential synthetic lethal interaction was 
considered to exist if three or more of the four combinations of target DDR 
gene/PARG siRNA showed at least 20% reduction in viability compared to 
controls (figure 1D). By these criteria disruption of BRCA1, BRCA2, PALB2, 
RAD51D, BRIP1, BARD1, MRE11, NBN, RAD50, TP53, and FAM175A can 
be considered synthetic lethal with PARG depletion. 
 
3.2 A chemical screen for genetic sensitivities to PARG inhibition. 
Previously, Gallotannin was used to inhibit PARG showing complete inhibition 
of PAR polymer degradation at 10 PM 39. However there are concerns over 
the specificity of Gallotannin 43,44. We therefore also used a newly identified 
specific PARG inhibitor PDD00017273 40 . To confirm PARG inhibition by this 
new agent, recombinant PARP1 was used to add biotinylated PAR to 
histones; recombinant PARG was then added and loss of PAR in the 
presence or absence of PDD00017273 was assessed (figure 2A). 
PDD00017273 caused a dose dependent inhibition of PARG with significant 
inhibition being seen between 0.1 and 1 PM. This is consistent with previous 
reports of its activity 40,45. To determine whether PDD00017273 also inhibits 
PARG in cells, the MCF7 cell line was treated for 24 hours with 0.3 PM and 1 
PM PDD00017273 in the absence of any exogenous DNA damage. Western 
blotting of the resultant cell lysates revealed an increase in PAR polymers at 
0.3 PM (figure 2B), confirming that PDD00017273 does indeed inhibit 
degradation of PAR polymers in cells. Surprisingly, in the recombinant protein 
assay less PARG inhibition was seen at 1 PM than 0.3 PM PDD00017273. In 
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western blotting, quantification of 3 repeats did not demonstrate this 
difference, but close examination of each repeat revealed that PARG 
inhibition was less consistent at the higher dose (supplementary data S2A). 
Cells treated with 10 PM Gallotannin or the PARP inhibitor Olaparib for 24 
hours showed the expected increase and reduction of PAR polymers 
respectively (figure 2B). Consistent with our previous findings, PARG 
inhibition alone reduced MCF7 cell survival in long-term clonogenic survival 
assays, while PARP inhibition had no significant effect on survival (figure 2C). 
The same panel of target DDR gene siRNAs were then used to determine the 
effect of gene deletion on PARG inhibitor sensitivity. The individual siRNAs for 
each gene were pooled then each experiment was repeated in triplicate on 
three separate occasions. Survival was determined by clonogenic survival 
assay in MCF7 cells using 10 PM Gallotannin or 0.3 PM PDD00017273, as 
these doses gave maximum inhibition with the lowest toxicity (figure 2A-C) 39. 
To take account of the effect of depleting each gene, survival fractions were 
calculated as the fraction of cells surviving following treatment with DDR gene 
siRNA and inhibitor compared to DDR gene siRNA alone (figure 2D and E). 
Compared to similarly treated scrambled siRNA treated control cells, 
decreased survival was seen in BRCA1, BRCA2, PALB2, FAM175A, and 
BARD1 depleted cells following treatment with 10 PM Gallotannin or 0.3 PM 
PDD00017273. Depletion of MRE11A increased sensitivity only to 
PDD00017273, while PTEN and RAD51D depletion sensitized only to 
Gallotannin. Under the same experimental conditions, survival was reduced in 
BRCA1, BRCA2, PALB2, RAD51C, BARD1, MRE11A, RAD50, ATM, 
FAM175A and XRCC2 depleted MCF7 cells treated with the PARP inhibitor 
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Olaparib (supplementary data S2B). 
 
3.3 An siRNA screen for increased DNA damage with PARG depletion. 
The synthetic lethal effects of PARG with BRCA2 are reported as due to 
increased levels of unrepaired DNA damage in cells. The formation of JH2AX 
foci is a general marker of DNA damage. SiRNA mediated depletion of 
BRCA1, BRCA2, PALB2, FAM175A, and BARD1 combined with PARG 
siRNA resulted in increased JH2AX foci compared to depletion of each DDR 
gene alone (figure 3 and S3), suggesting increased levels of DNA damage 
occur and/or that repair is reduced when PARG expression is reduced in 
these genetic backgrounds. Interestingly, depletion of PARG in a BRIP1, 
PTEN or CDKN2A depleted background resulted in significantly fewer JH2AX 
foci than when BRIP1, PTEN or CDKN2A where depleted alone, suggesting a 
different functional relationship between these genes.  
 
3.4 BRCA1, BRCA2, PALB2, FAM175A and BARD1 depleted cells are 
confirmed as sensitive to PARG depletion and inhibition. 
 
There were just five DDR genes that resulted in decreased cell viability in 
response to PARG siRNA, and decreased survival with Gallotannin and 
PDD00017273 - BRCA1, BRCA2, PALB2, FAM175A and BARD1 (table 1). 
Significantly, these were the only genes in the screen that resulted in 
upregulated JH2AX foci formation (table 1). BRCA1, BRCA2, PALB2, 
FAM175A and BARD1, were therefore examined further. During the PARG 
siRNA screening process, cell viability was analysed by MTT assay. To 
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validate these findings, combinations of two different individual target DDR 
gene siRNAs with each of two different individual PARG siRNAs were 
transfected into MCF7 cells along with the relevant controls, and cell survival 
determined by clonogenic survival assay. The experiment was repeated on 
three separate occasions and statistical significance calculated. The efficiency 
of siRNA mediated depletion was ensured by western blotting (supplementary 
data S4). For each gene there was a reduction in protein expression that was 
accompanied by a reduction in survival in at least three of four combinations 
of PARG siRNA with target DDR gene siRNA compared to target DDR gene 
alone (figure 4A). For BRCA2 a synthetic lethal relationship has previously 
been demonstrated using siRNA, therefore here the CAPAN-1 cell line, which 
carries a naturally occurring 6174delT mutation in one BRCA2 allele 
accompanied by loss of the wild-type allele was used to demonstrate further 
the clinical potential of PARG inhibitors (figure 4B). Compared to the control 
BRCA2 wildtype BXPC3 cells 46, CAPAN-1 cells were more sensitive to both 
Gallotannin and PDD00017273.  
 
During the inhibitor screening process (figure 2) target DDR gene siRNA were 
pools of individual siRNAs; therefore to further validate these results each of 
two different target DDR gene siRNAs were used in combination with 
Gallotannin and PDD00017273 and survival assayed by clonogenic assay on 
three separate occasions (figure 4C). Depletion of each of the five DDR genes 
resulted in significant reduction in cell survival compared to controls. 
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These data together confirm the validity of PARG as a mono-therapeutic 
target in BRCA1, BRCA2, PALB2, FAM175A and BARD1 depleted cells.  
 
3.5 PARG inhibition/depletion stalls replication forks and induces DNA 
damage that requires HRR for repair. 
Gallotannin has previously been shown to increase JH2AX foci formation. 
These foci were reduced in cells co-treated with the replication inhibitor 
aphidicolin 39, and thus the foci were considered to be due to DNA aberrations 
at replication forks. Synthetic lethality was therefore suggested to be the result 
of a lack of BRCA2 for repair/restart of the replication forks. Consistent with 
this, Gallotannin, PDD00017273 and PARG siRNA all induced JH2AX foci 
formation compared to the respective controls (figure 5A). Previously, we 
have shown that inhibition of PARP caused replication fork stalling 14, thus the 
progression of single replication forks was examined using a DNA fibre assay. 
In this assay, inhibition of PARG resulted in increased replication fork stalling 
(figure 5B) directly demonstrating an effect of PARG inhibition on replication 
forks. Consistent with an increased requirement for certain HRR proteins 
following inhibition or depletion of PARG, Gallotannin, PDD00017273 and 
PARG siRNA all increased formation of RAD51 foci compared to the 
respective controls (figure 5C).  
 
3.6 BRCA1, BRCA2, PALB2, FAM175A and BARD1 are all required for 
HRR following PARG depletion. 
The function of BRCA1, BRCA2, PALB2, FAM175A, and BARD1 in HRR was 
demonstrated by a reduction in the number of endogenous RAD51 foci seen 
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in cells (figure 6A) and confirmed using a GFP reporter assay (supplementary 
figure S5). Further, PARG depletion-induced RAD51 foci formation was 
reversed when cells were co-depleted of PARG and BRCA1, BRCA2, PALB2, 
FAM175A, or BARD1 (figure 6B), again suggesting that cell death is due to a 
lack of repair of DNA damage/inability to restart stalled replication forks. 
Interestingly, while PARG depletion and inhibition induced Rad51 foci 
formation in the absence of exogenous DNA damage (figure 5E and 6B), it did 
not increase HRR at an I-SceI induced double strand break (figure 6A), 
indicative of the difference in response of cells to various types of DNA 
lesions. 
 
Together these data support our previous findings and a model whereby 
inhibition or depletion of PARG leads to fork stalling and fork aberrations, 
resulting in signalling and recruitment of HRR proteins for repair. Therefore in 
the absence of these HRR proteins, PARG depleted or inhibited cells cannot 
survive. 
 
4. Discussion  
Our use of a novel class of PARG inhibitor to selectively kill tumour cells with 
particular genetic defects, combined with our data generated using 
Gallotannin and PARG siRNA support the future development of PARG 
inhibitors as mono-therapeutic agents. This is the first such report of a screen 
for synthetic lethal interactions (or more correctly induced cell death) with 
PARG and the first potential synthetic lethal use for the novel PARG inhibitor 
PDD00017273 40. It is worth noting that the PDD00017273 induced reduction 
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in long-term survival seen here in MCF7 cells, is in contrast to that seen with 
the same agent in a short-term assay in HeLa cells 40, this could be due to 
cellular specificity or the long-term versus short-term effects of the drug.  
 
Here, BRCA1, BRCA2, PALB2, FAM175A, and BARD1 were all seen to be 
synthetic lethal with PARG following siRNA mediated depletion and inhibition 
of PARG activity, each gene has been associated with breast cancer and 
ovarian cancer 47-50, as well as prostate cancer (BRCA1, BRCA2, PALB2) 50-53 
and pancreatic cancer (PALB2, BRCA1, BRCA2) 54-57 thus PARG inhibition 
may have clinical potential in some of these patients. However, another report 
using PARG siRNA in a different cellular background fails to confirm that 
BRCA1 defects lead to sensitivity to PARG depletion 58, perhaps highlighting 
the importance of other genetic factors. Indeed MCF7 cells have over 30 
known nonsynonymous mutations including DNA-PK and ERCC6. It would 
therefore be interesting to examine if these synthetic lethal relationships hold 
true for other cancer cell lines or other disease areas. In addition given the 
breast cancer focused screen performed here, a full screen of synthetic 
lethality with PARG inhibitors is warranted. The full clinical potential of PARG 
inhibitors will be the subject of future investigations.  
 
While BRCA1, BRCA2 and PALB2 have been associated with HRR at DNA 
double strand breaks and replication-fork associated DNA damage 59-61, the 
role of FAM175A and BARD1 are less well described. FAM175A (ABRAXAS) 
has been implicated in the repair of ionizing radiation and crosslink induced 
DNA damage, but it is reported as not being involved in response to the 
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replication inhibitor hydroxyurea 62. Our FAM175A and BARD1 data 
demonstrate reduced I-SceI induced HRR and reduced RAD51 foci formation 
following PARG depletion, supporting a function for each at both double 
strand breaks and replication associated DNA lesions. 
 
In previous studies the relative degree of sensitivity to PARP or PARG 
inhibition was different between cell lines 40, perhaps indicative of a different 
pharmacology in different genetic backgrounds. Here in parallel to PARG 
inhibitor screening, sensitivity to the PARP inhibitor Olaparib was carried out, 
allowing direct comparison of the role of various DDR genes in sensitivity to 
PARG inhibition within the same genetic background. When comparing PARP 
and PARG synthetic lethal interactions, we saw that many of the same genes 
are implicated (e.g. BRCA1, BRCA2, PALB2, BARD1, and FAM175A), likely 
reflecting the function of PARG to reverse PARP activity and allow repair to 
proceed. In contrast, RAD51C, ATM, and XRCC2 depleted cells were 
sensitive only to PARP inhibition, and showed no effect with PARG siRNA, 
Gallotannin or with PDD00017273. The precise reasons for these differences 
are not clear but they do argue that not all functions of PARP and PARG are 
common. Perhaps it is worth noting that unlike BRCA1/2, RAD51C and 
XRCC2 are thought to act late in HRR, downstream of RAD51 foci formation. 
Using siRNA, PTEN has previously been reported as not having a synthetic 
lethal relationship with PARG 58, here we confirm this with a PARG inhibitor. 
Interestingly though, co-depletion of BRIP1 or PTEN and PARG resulted in 
significantly fewer JH2AX foci compared to BRIP1/PTEN alone, suggesting 
that BRIP1 and PTEN may have a complex functional interaction with PARG, 
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which maybe important for future understanding of the function of PARG 
during DNA damage repair.  
 
Importantly, PARG inhibition/depletion was capable of killing BRCA1, BRCA2, 
PALB2, FAM175A, or BARD1 depleted cells in the absence of any exogenous 
DNA damaging agents. We previously demonstrated that the increase in DNA 
damage signalling following PARG inhibition was dependent on active 
replication 39. Furthermore, PARG is essential for recovery from long-term 
replication stress 38. Thus, it is likely that the function of HRR proteins is to 
restore replication following PARG inhibition, however the nature of PARG-
induced replication stress and the role of HRR proteins in this process is less 
clear. Additionally, we have previously argued that the reason for synthetic 
lethality is an inability to undergo HRR for collapsed replication fork restart 39. 
HRR is known to be required to restart collapsed replication forks 63, and the 
poly(ADP-ribosyl)ation activity of PARP1 is known to stabilize DNA replication 
forks 64,65. PARG depletion/inhibition has been seen to increase the number of 
endogenous reversed replication forks and post-replicative ssDNA breaks 37, 
raising the possibility that in the absence of PARG, HRR could also have a 
function in restarting these reversed forks. Consistent with either hypothesis is 
our finding that PARG inhibition in the absence of any exogenous damage 
stalls the replication fork and that endogenous RAD51 foci are induced 
following PARG inhibition or depletion. The nature of the DNA lesion/s 
induced by PARG inhibition/depletion and the function of various DNA repair 
proteins (including PARP and PARG themselves) has been and is likely to 
continue to be a subject of debate. 
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While depletion/inhibition of either PARG or PARP increases endogenous 
RAD51 foci formation, PARG depletion/inhibition results in decreased HRR at 
a site specific DNA double strand break, which is in contrast to the finding that 
HRR at the same site in PARP-inhibited cells is normal 66. The reason for the 
difference between PARP and PARG depletion is possibly because PARP 
plays a regulating role rather than essential role in HRR, thus its absence 
does not prevent HRR. However, irreversible binding of PAR to DSBs is likely 
to result in failure of the ability of other proteins to complete HRR. 
 
5. Conclusion 
In summary, we show that disruption of the HRR associated proteins BRCA1, 
BRCA2, PALB2, FAM175A and BARD1 are synthetic lethal with depletion or 
inhibition of PARG. PARG inhibition stalls replication forks, triggers DNA 
damage signalling, and HRR protein accumulation in repair foci, suggestive of 
a function of these proteins in replication fork restoration. Although further 
testing is needed to validate findings in other cellular backgrounds and in pre-
clinical studies, our data do suggest that the future development of clinically 
applicable PARG inhibitors may hold promise for treatment of some types of 
HRR-deficient tumours. 
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Table 1: Summary of results following depletion of target DDR gene 
using siRNA in combination with PARG siRNA or PARG inhibitors.  
 
Figure legends 
Figure 1: Synthetic lethal screen using siRNA 
(A) Relative expression of mRNA for each test gene compared to scrambled 
control 24 hours post transfection as measured by qRT-PCR and normalized 
to U1 snRNA. Letters above target gene names refer to separate oligos (a-d) 
for each gene. (B) Protein expression of PARG and PARP 48 hours post 
transfection with each PARG siRNA, representative western blot and mean 
and standard deviation of quantification of 3 independent repeats are shown. 
(C)  MCF7 cell viability 5 days post transfection with each PARG siRNA 
measured by MTT assay, mean and standard deviation of four independent 
repeats are shown. (D) MCF7 cell viability as measured by MTT assay 5 days 
post transfection with combinations of individual siRNA oligos. For each target 
DDR gene siRNA + PARG siRNA survival fraction is calculated compared to 
DDR gene alone, mean of two independent repeats is shown.  
 
Figure 2: Synthetic lethal screen using PARG inhibitors 
(A) Quantification of PARG activity in the presence of increasing 
concentrations of PDD00017273 as measured by the ability of recombinant 
PARG to hydrolyse biotinylated PAR polymers from histones. (Bi) Western 
Blot for poly(ADP-ribose) (PAR), PARP1, PARG and , in MCF7 cells 
control (DMSO), treated with PARG inhibitors (Gallotannin (GLTN) and 
PDD00017273) or PARP inhibitor (Olaparib). (Bii) Quantification represents 
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mean intensity of PAR over 3 independent repeats relative to tubulin loading 
control. (C) Survival fraction of MCF7 cells untreated (DMSO), treated with 
PARG inhibitors (GLTN and PDD00017273) or PARP inhibitor (Olaparib) as 
measured by clonogenic survival assay, mean and standard deviation of three 
independent repeats are shown. Statistical significance was calculated using 
tKH 6WXGHQW¶V 7-test, compared to DMSO control. (D) Survival fraction of 
pooled target DDR gene siRNA transfected MCF7 cells treated with PARG 
inhibitors Gallotannin (GLTN) (E) PDD00017273 compared to corresponding 
siRNA transfected DMSO treated cells. Survival was measured by clonogenic 
survival assay; mean and standard deviation of 3 independent repeats are 
VKRZQ 6WDWLVWLFDO VLJQLILFDQFH ZDV FDOFXODWHG XVLQJ WKH 6WXGHQW¶V 7-test, 
comparing DDR gene + inhibitor to scrambled control + inhibitor where * = 
p<0.05, **= p<0.01. 
 
Figure 3: JH2AX formation screen with siRNA 
Fold increase in cells with greater than 5 JH2AX foci / cell in MCF7 cells 24 h 
post transfection with combinations of pools of target DDR gene siRNA plus 
pooled PARG siRNA compared to corresponding target DDR gene alone. 100 
cells were counted on three separate occasions; mean and standard deviation 
DUHVKRZQ6WDWLVWLFDOVLJQLILFDQFHZDVFDOFXODWHGXVLQJ WKH6WXGHQW¶V7-test, 
compared to scrambled siRNA + PARG siRNA control, where * = p<0.05, **= 
p<0.01. Representative images are shown in supplementary data S3. 
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Figure 4: Confirmation of synthetic lethal relationships by clonogenic 
survival assay. 
(A) Survival fraction of MCF7 cells as measured by clonogenic survival assay 
14 days post transfection with siRNA. Combinations of two different siRNA 
targeting PARG (PARG1 or PARG3) are combined with two different siRNA 
targeting the test DDR gene (indicated by a letter after the test gene name). 
For each DDR gene siRNA + scrambled/PARG siRNA survival fraction is 
calculated compared to corresponding scrambled/PARG siRNA alone. 
6WDWLVWLFDO VLJQLILFDQFH ZDV FDOFXODWHG XVLQJ WKH 6WXGHQW¶V 7-test, comparing 
DDR gene + PARG gene siRNAs to DDR gene + scrambled control siRNAs. 
(B) Survival fraction of wildtype (BXPC3) and BRCA2 deficient (CAPAN1) 
cells treated with DMSO, PARP inhibitor (Olaparib), or the PARG inhibitors 
(gallontannin (GLTN) and PDD00017273), as measured by clonogenic 
survival assay. 6WDWLVWLFDO VLJQLILFDQFHZDVFDOFXODWHGXVLQJ WKH6WXGHQW¶V7-
test, comparing BXPC3 to CAPAN1 for each treatment. (C) Survival fraction 
of MCF7 cells as measured by clonogenic survival assay 14 days post 
transfection with DDR gene siRNA with addition of the PARG inhibitors 
Gallotannin (GLTN) or PDD00017273. For each DDR gene siRNA + 
DMSO/inhibitor survival fraction is calculated compared to corresponding 
DMSO/inhibitor + scrambled siRNA. Statistical significance was calculated 
XVLQJ WKH 6WXGHQW¶V 7-test, comparing PARG inhibitor treated cells to 
respective DMSO control.  In each case mean and standard deviation of 3 
independent repeats are shown. * = p<0.05, **= p<0.01. 
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Figure 5: PARG depletion/inhibition disrupts replication forks and 
induces accumulation of JH2AX and RAD51 foci. 
(A) Percentage of cells with greater than 5 JH2AX foci / cell in MCF7 cells 24 
hours post treatment with control (DMSO), PARP inhibitor (Olaparib (OLA)), 
the PARG inhibitors (gallontannin (GLTN) and PDD00017273), scrambled 
siRNA and PARG siRNA (a pool of PARG1 + PARG3 siRNA). Example 
images are shown. 6WDWLVWLFDOVLJQLILFDQFHZDVFDOFXODWHGXVLQJWKH6WXGHQW¶V
T-test, compared to DMSO or scrambled control, where * = p<0.05, **= 
p<0.01, ***= p<0.001. (B) DNA fibre analysis of replication fork stalling in 
MCF7 cells treated with PARP and PARG inhibitors. Cells were incubated in 
inhibitor and then pulse labelled with CldU, for 20 min, and labeled switched 
to IdU for 20 min. Fork stalling was calculated as a % of CIdU only labeled 
tracts (red) from continuous forks (CIdU (red) and IdU (green) labeled tracts). 
Example images of replication forks are shown. At least 100 forks were 
counted on each of three separate occasions. Data bars present the mean 
and standard deviation of three independent experiments. Statistical 
VLJQLILFDQFH ZDV FDOFXODWHG XVLQJ WKH 6WXGHQW¶V 7-test compared to DMSO 
control. (C) Percentage of cells with greater than 10 RAD51 foci/cell in MCF7 
cells 24 hours post treatment with control (DMSO), PARP inhibitor (Olaparib 
(OLA)), the PARG inhibitors (Gallotannin (GLTN) and PDD00017273), 
scrambled siRNA and PARG siRNA (a pool of PARG1 + PARG3 siRNA). 
Example images are shown. Statistical significance was calculated using the 
6WXGHQW¶V7-test, compared to DMSO or scrambled control.  
 
Figure 6: Homologous recombination after PARG depletion. 
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(A) Percentage of cells with greater than 10 RAD51 foci / cell in MCF7 cells 
24 hours post treatment with scrambled or target DDR gene siRNA. (B) 
Percentage of cells with greater than 10 RAD51 foci / cell in MCF7 cells 24 
hours post treatment with scrambled, PARG siRNA (a pool of PARG1 + 
PARG3 siRNA) and PARG + target DDR gene siRNA. For each 100 cells 
were counted on 3 separate occasions and mean and standard deviation 
shown. 6WDWLVWLFDO VLJQLILFDQFH ZDV FDOFXODWHG XVLQJ WKH 6WXGHQW¶V 7-test, 
compared to PARG siRNA alone control, where * = p<0.05, **= p<0.01, ***= 
p<0.001. 
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S1 
MCF7 cell viability five days post transfection with each target DDR gene 
siRNA compared to scrambled siRNA measured by MTT assay, mean and 
SEM of two independent repeats are shown. 
 
S2 
A: Three repeats of western blotting for PAR following incubation with PARG 
or PARP inhibitors. Each repeat is quantified relative to tubulin.  
 
B: Survival fraction of target DDR gene siRNA transfected MCF7 cells treated 
with the PARP inhibitor Olaparib (1 PM). Survival was measured by 
clonogenic survival assay, mean and standard deviation of three independent 
repeats are shown. Statistical significaQFHZDVFDOFXODWHGXVLQJWKH6WXGHQW¶V
T-test, compared to drug + scrambled control. 
 
S3  
ȖH2AX foci following treatment with pooled target DDR gene siRNA with or 
without pooled PARG gene siRNA 
 
S4 
Western blot to demonstrate depletion of target DDR genes and PARG 
following 48 h treatment with corresponding siRNA 
 
S5 
Relative recombination frequency. The DR-GFP reporter consists of two 
defective GFP genes. Expression of I-SceI endonuclease results in a double-
strand break (DSB) at the I-SceI site in the SceGFP gene which can be 
repaired using the homologous sequence in the iGFP gene to generate GFP 
positive cells which are quantified by flow cytometry. The mean and standard 
deviation of percentage GFP positive cells in MCF7 cells 24 hours post 
transfection with siRNA as indicated are shown. Statistical significance was 
FDOFXODWHGXVLQJWKH6WXGHQW¶V7-test, compared to scrambled control, using 
three independent repeats. 
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TEST DDR 
GENE 
Reduced cell 
viability + 
PARG siRNA 
Reduced cell 
survival + 
GALLOTANNIN 
Reduced cell 
survival + 
PDD00017273 
Increased 
JH2AX 
BRCA1 YES YES YES YES 
BRCA2 YES YES YES YES 
PALB2 YES YES YES YES 
RAD51C NO NO NO NO 
CHEK2 NO NO NO NO 
RAD51D YES YES NO NO 
BRIP1 YES NO NO REDUCED 
BARD1 YES YES YES YES 
MRE11A YES NO YES NO 
NBN YES NO NO NO 
RAD50 YES NO NO NO 
TP53 YES NO NO NO 
PTEN NO YES NO REDUCED 
STK11 NO NO NO NO 
ATM NO NO NO NO 
FAM175A YES YES YES YES 
XRCC2 NO NO NO NO 
CDKN2A NO NO NO REDUCED 
 
 
 
 






